Does PT-141 work for men?

This site's PT-141 studies do not measure whether it works in men. The two RECONNECT studies behind the approval enrolled 1,267 women with low sexual desire that causes distress, who had not reached menopause, over 24 weeks. Desire scores rose by 0.35 on a desire questionnaire (the FSFI desire scale) compared with a dummy shot. Nausea, flushing, and headache each showed up in 10% or more. The 52-week follow-on in 684 women, where everyone knew they were getting the drug, tracked safety. The US legal field is FDA approved, prescription only, as Vyleesi, for that one use in women. Use in men is off-label, or a research-chemical vial, which is not the product used in the studies. A related molecule, melanotan II, produced erections in 8 of 10 men in a 1998 study where each man tried both the drug and a dummy. That is not a PT-141 result. This FAQ does not invent a male response rate.

Educational use only. This database summarizes published research and is not medical advice. Where a dose appears it is a record of what a trial or clinic ran, or what people describe doing, with its source attached. Nothing here is a recommendation for personal use.

Part of further names and published absences. Leftover harvested questions after the first two absence sets: more brand versus molecule names, side effects the citations did not count, compounding formulas this catalogue does not hold, national FDA and Australia fields, trial windows rather than an onset clock, named combinations with no interaction table, and oral routes that have not been studied.